Cristal Therapeutics progresses nanomedicine CriPec-docetaxel to Phase Ib development
This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products.
Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has begun a Phase Ib clinical program of its lead nanomedicine candidate CriPec-docetaxel in patients with solid tumours. This CriPec-docetaxel program will evaluate the optimal frequency and dosing schedule for Phase II clinical efficacy trials, as well as examining the distribution and uptake of this nanomedicine.
CriPec-docetaxel is a new drug modality that entraps docetaxel (Taxotere), a clinically validated chemotherapy, as its therapeutic payload into nanoparticles. This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products, such as the toxic systemic side effects.
The Phase Ib program is being initiated based on preliminary positive Phase Ia results from the open-label, safety and pharmacokinetic study, which suggest that CriPec-docetaxel can be administered at therapeutic dose levels that are safe and well tolerated. CriPec-docetaxel also demonstrated a unique and improved pharmacokinetic profile over Taxotere and other docetaxel-based drug candidates.
Dr Joost Holthuis, Cristal Therapeutics’ CEO and co-founder said: “Progressing CriPec-docetaxel to a Phase Ib program is an important milestone, and highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study. We look forward to the results of the consolidated Phase I program.”
The Phase Ib study is being conducted at the Department of General Medical Oncology, University Hospitals Leuven, Belgium and at the following three clinical centres across the Netherlands: Erasmus M.C. Cancer Institute, Rotterdam, the Vrije Universiteit Medical Centre, Amsterdam and the University Medical Centre Groningen.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance